Institut Sainte Catherine — Clinical Trial Site

71 Registered trials

29 Currently recruiting

Organisation

Institut Sainte Catherine

Location

Avignon, France

Identifier

ORG-100042952

Address

250 Chemin De Baigne Pieds, 84000, France

Departments

033007:Medical Oncology
Breast Oncology
Département de dermatologie
Département de radiothérapie
Digestive Oncology
Internal Medicine
Medical Oncology
Medical Oncology Department
NA
Oncologie
Oncologie Médicale
Oncologie- Radiothérapie
Oncology
Oncology - radiotherapy
Oncology Radiotherapy
Oncology-Radiotherapy
Radiology/Oncology
Radiotherapy
Recherche clinique, cancerologie
Service d'oncologie
Service d'oncologie médicale
Service d'Oncologie-Radiothérapie
Service d’Oncologie Médicale
Service de Pneumologie
Service De Radiotherapie
Service Oncologie
Unite Onco-Digestif

Clinical trials at this site (71)

Search interface

Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended

2023-510390-33-00 HER2-negative breast cancer patients with high relapse 5 2020-10-23
A Phase 3 Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment … Ended

2023-506365-64-00 Deleterious Germline or Somatic Homologous Recombinatio 5 2020-10-16
Phase III study of Pembrolizumab plus chemoradiation vs chemoradiation along for patients with muscle invasive bladder cancer Ended

2023-503500-87-00 Muscle Invasive Bladder Cancer 11 2020-03-17
A clinical study evaluating the benefits of apalutamide, a novel drug targeting prostate cancer growth, in combination with radiotherapy and… Ended

2024-514829-36-00 High-risk biochemically-relapsed prostate adenocarcinom 5 2019-12-02
Palbociclib for HR positive Isolated Local or Regional Recurrence of Breast Cancer Ended

2024-510776-20-00 Female or male patients with histologically confirmed H 5 2019-10-25
Phase III randomized trial of atezolizumab in elderly patients with advanced Non-Small-Cell Lung Cancer and receiving monthly carboplatin wi… Ended

2024-515946-17-00 Non Small Cell Lung Cancer 5 2019-07-22
A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea… Ended

2023-510357-42-00 hormone receptor (HR)-positive, HER2-negative, early br 5 2019-05-22
Testing a new targeted therapy trastuzumab deruxtecan (DS-8201a) against ado-trastuzumab emtansine (T-DM1) for patients with advanced stage … Ended

2024-511204-16-00 Metastatic breast cancer 5 2019-01-23
Phase III study of pembrolizumab for high-risk early-stage ER+/HER2– breast cancer Ended

2023-506921-12-00 ER+/HER2- Breast Cancer 5 2018-12-27
Randomized trial evaluating the addition of nivolumab to cisplatin-radiotherapy combination for treatment of cancers of the head and neck Ended

2024-513206-65-00 resected squamous cell carcinoma of head and neck 5 2018-08-10
IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting Ended

2024-517489-41-00 High-risk stage III colon cancer 5 2017-03-27
Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations Ended

2024-514904-14-00 Patients with metastatic or unresectable locally advanc 4 2014-10-08
Chemotherapy or chemotherapy + hormonotherapy in women over 70 with HER2 receptor-negative but estrogen receptor-positive breast cancer acco… Ended

2024-516996-34-00 oestrogen-receptor (ER)-positive HER2-negative breast c 5 2012-04-12
Study comparing radiotherapy combined with cetuximab + Xevinapant (study drug) with radiotherapy combined with cetuximab + placebo in patien… Ended

2022-502584-38-00 Locally advanced squamous cell carcinoma of the head an 5 2023-12-12
Randomized, non-comparative, open-label early phase Ib study with OBT076 or OBT076 followed by Balstilimab in patients with Adenoid Cystic C… Ended

2023-503270-20-00 recurrent or metastatic Adenoid Cystic Carcinoma of the 3 2023-11-29
Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) me… Ended

2022-502372-22-01 Metastatic Breast Cancer HR+, HER2- 4 2023-10-19
Study Comparing Bemarituzumab plus Chemotherapy with Placebo and Chemotherapy in Previously Untreated Advanced Gastric or Gastroesophageal J… Ended

2023-505457-40-00 Previously Untreated Advanced Gastric or Gastroesophage 5 2022-02-02
Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Ga… Ended

2023-504834-23-00 Advanced/Metastatic Gastroesophageal Adenocarcinoma 11 2021-02-24
A Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherap… Ended

2022-501531-16-00 esophageal carcinoma 5 2020-01-24
Olaparib Plus Pembrolizumab Compared to Chemotherapy Plus Pembrolizumab After Initial Treatment With Chemotherapy Plus Pembrolizumab in Trip… Ended

2022-500418-24-00 Locally Recurrent Inoperable or Metastatic Triple Negat 10 2020-01-17
Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC Ended

2022-500785-10-00 Metastatic Castration-Resistant Prostate Cancer 5 2019-08-23
Trial evaluating the tolerance and safety of durvalumab - radiotherapy combination for treatment of cancers of the head and neck Ended

2024-513977-31-00 Untreated squamous cell carcinoma of the head and neck 4 2019-07-17
A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eli… Ended

2022-501970-20-01 Cis-eligible Muscle-invasive bladder cancer. 5 2019-06-07